Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154

Cancer Research

Volumn 57, Issue 13, 1997, Pages 2569-2574

  Mackey, Matthew F ^a   Gunn, Jason R ^a   Ting, Patrick P ^a   Kikutani, Hitoshi ^b   Dranoff, Glen ^c   Noelle, Randolph J ^a   Barth Jr , Richard J ^a,d  

^a NORRIS COTTON CANCER CENTER   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CORYNEBACTERIUM PARVUM VACCINE; GLYCOPROTEIN GP 39; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LIGAND; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNOGENICITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD40; CANCER VACCINES; CD40 LIGAND; FEMALE; IMMUNITY, CELLULAR; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0030797455     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Nat. Acad. Sci. USA, 90: 3539-3543, 1993.
2. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., III, McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol., 154: 6466-6674, 1995.
3. Hock, H., Dorsch, M., Kunzendorf, U., Uberla, K., Qin, Z., Diamantstein, T., and Blankenstein, T. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res., 53: 714-716, 1993.
4. + T cells by B7-transfected melanoma cells. Science (Washington, DC), 259: 368-370, 1993.
5. Grewal, I. S., Xu, J., and Flavell, R. A. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature (Lond.), 78: 617-620, 1995.
6. Grewal, I. S., Foellmer, H. G., Grewal, K. D., Xu, J., Hardardottir, F., Baron, J. L., Janeway, C. A., Jr., and Flavell, R. A. Requirement for CD40 ligand in costimulation induction, T-cell activation, and experimental allergic encephalomyelitis. Science (Washington DC), 273: 1864-1867, 1996.
7. Yang, Y., and Wilson, J. M. CD40 ligand-dependent T-cell activation: requirement of B7-CD28 signaling through CD40. Science (Washington DC), 273: 1862-1864, 1996.
8. Campbell, K. A., Ovendale, P. J., Kennedy, M. K., Fanslow, W. C., Reed, S. G., and Maliszewski, C. R. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity, 4: 283-289, 1996.
9. Durie, F. H., Aruffo, A., Ledbetter, J., Crassi, K. M. Green, W. R., Fast, L. D., and Noelle, R. J. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft versus host disease. J. Clin. Invest., 94: 1333-1338, 1994.
10. Armstrong, C. A., Botella, R., Galloway, T. H., Murray, N., Kramp, J. M., Song, I. S., and Ansel, J. C. Antitumor effects of granulocyte macrophage colony-stimulating factor production by melanoma cells. Cancer Res., 56: 2191-2198, 1996.
11. Larsen, C. P., Ritchie, S. C., Hendrix, R., Linsley, P. S., Hathcock, K. S., Modes, R. J., Lowry, R. P., and Pearson, T. C. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol., 152: 5208-5219, 1994.
12. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res., 55: 1099-1104, 1995.
13. Lenschow, D. J., Walunas, T. L., and Bluestone, J. A. CD28/B7 system of T-cell costimulation. Annu. Rev. Immunol., 14: 233-258, 1996.
14. Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I., and Banchereau, J. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med., 180: 1263-1272, 1994.
15. Barth, R. J., and Mule, J. J. Cytokine gene transfer into tumor cells: animal models. In: R. Moen and M. Brenner (eds.), Gene Therapy in Cancer, pp. 73-93. New York: Marcel Dekker, Inc., 1996.
16. + tumor-infiltrating lymphocytes. J. Exp. Med., 173: 647-658, 1991.
17. + T cells. J. Immunol., 154: 5071-5079, 1995.
18. Trinchieri, G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol., 13: 251-276, 1995.
19. Kamanaka, M., Yu, P., Yasui, T., Yoshida, K., Kawabe, T., Horii, T., Kishimoto, T., and Kikutani, H. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity, 4: 275-281, 1996.
20. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., and Storkus, W. J. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153: 1697-1706, 1994.
21. Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., Suematsu, S., Yoshida, N., Kishimoto, T., and Kikutani, H. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity, 1: 167-178, 1994.
22. Shu, S., and Rosenberg, S. A. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res., 45: 1657-1663, 1985.
23. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by 1L-2 gene. J. Immunol., 149: 3627-3635, 1992.
24. Noelle, R. J., Roy, M., Shepherd, D. M., Stamenkovic, I., Ledbetter, J. A., and Aruffo, A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA, 89: 6550-6554, 1992.
25. Spiess, P. J., Yang, J. C., and Rosenberg, S. A. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst., 79: 1067-1075, 1987.
26. Foy, T. M., Shepherd, D. M., Durie, F. H., Aruffo, A., Ledbetter, J. A., and Noelle, R. J. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J. Exp. Med., 178: 1567-1575, 1993.
27. Geiger, J. D., Wagner, P. D., Cameron, M. J., Shu, S., and Chang, A. E. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J. Immunother., 13: 153-165, 1993.
28. Yamasaki, S., Okino, T., Chakraborty, N. G., Adkisson, W. O., Sampieri, A., Padula, S. J., Mauri, F., and Mukherji, B. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage colony-stimulating factor-cultured macrophages from HLA-A1 melanoma patients. Cancer Immunol. Immunother., 40: 268-271, 1995.
29. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
30. Shu, S., and Rosenberg, S. A. Adoptive immunotherapy of newly induced sarcoma: immunologic characteristics of effector cells. J. Immunol., 135: 2895-2903, 1985.
31. + T cells. J. Immunol., 151: 2497-2510, 1993.
32. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol.. 12: 991-1045, 1994.
33. Inaba, K., Witmer-Pack, M., Inaba, M., Hathcock, K. S., Sakuta, H., Azuma, M., Yagita, H., Okumura, K., Linsley, P. S., and Ikehara, S. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med., 180: 1849-1860, 1994.
34. Alderson, M. R., Armitage, R. J., Tough, T W., Strockbine, L., Fanslow, W. C., and Spriggs, M. K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med., 178: 669-674, 1993.
35. + CTL response. J. Exp. Med., 183: 2129-2142, 1996.
36. Hollander, G. A., Castigli, E., Kulbacki, R., Su, M., Burakoff, S. J., Gutierrez-Ramos, J. C., and Geha, R. S. Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice. Proc. Natl. Acad. Sci. USA, 93: 4994-4998, 1996.
37. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., and Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T-cell stimulatory capacity: T-T help via APC activation. J. Exp. Med., 184: 747-752, 1996.
38. Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Kampgen, E., Romani, N., and Schuler, G. High level IL-12 production by murine dendritic cells: up-regulation via MHC class II and CD40 molecules and down-regulation by 1L-4 and IL-10. J. Exp. Med., 184: 741-746, 1996.
39. Stuber, E., Strober, W., and Neurath, M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med., 183: 693-698, 1996.
40. Stout, R. D., Suttles, J., Xu, J., Grewal, I. S., and Flavell, R. A. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol., 156: 8-11, 1996.
41. Kiener, P. A., Moran-Davis, P., Rankin, B. M., Wahl, A. F., Aruffo, A., and Hollenbaugh, D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J. Immunol., 155: 4917-4925, 1995.
42. + T cells in response to MIP-1 α and MIP-1 β. Science (Washington DC), 260: 355-358, 1993.